Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

Cisplatin 5Fluorouracil 4Capecitabine 4tislelizumab 2Radiation 2Gemcitabine 2toripalimab 1temoporfin 1nimotuzumab 1fludarabine 1Taxes 1Radiotherapy, Intensity-Modulated 1Maintenance Chemotherapy 1Drug Therapy 1Cyclophosphamide 1Cell Count 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Nasopharyngeal Carcinoma × fludarabine × Clear all
NCT03648697 2020-08-11

EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC

Fujian Cancer Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡